05.27.25 -- Lilly's CEO Building On The Trump Agenda

Stringent QC release testing throughout biologic production, as mandated by health authorities, ensures product safety and quality through evaluations of identity, purity, potency, and critical quality attributes.

With real-world examples and a vision that challenges the prevailing norms of biotech commercialization, this conversation offers a powerful look at what it takes to reshape the future of healthcare.

This study demonstrates the effect of different promoters and PREs (Post-Regulatory Element) on multiple CAR and transgenic TCR constructs on titer, integration, expression, and in vitro function.

Much of what we do in cell and gene therapy manufacturing is deeply habit-based. When employees understand the purpose behind a task, it supports their autonomy and competence.

As the landscape of CAR T-cell therapies evolves, these treatments are becoming more precise in targeting cancer cells and overcoming production challenges, and are poised to revolutionize oncology.

Manufacturing mRNA products is a complex and challenging process that requires careful consideration at each stage. Learn more about the challenges and intricacies involved.

Explore how uncovering molecular interactions can drive breakthroughs in disease understanding, drug discovery, and therapeutic innovation.

Partner with a specialized CDMO early in developing your cell and gene therapy to ensure a streamlined path from discovery to successful commercialization, avoiding costly pitfalls and delays.

Uncover how the strategies outlined here can optimize AAV manufacturing by reducing risk and balancing productivity, quality, and cost to meet the growing demands of gene therapy.

Learn how to navigate decision-making at critical steps and find solutions to key challenges in process development and scale-up to expedite oncolytic virus programs.

Unlike traditional drugs, AAV therapies require extensive characterization and testing, demanding varying degrees of analysis at each stage of development.

Experience the benefits of faster, more effective CAR-T cell production with this innovative three-day short-cycle process, designed to enhance patient treatment outcomes while reducing costs.

Examine the benefits of a new cryogenic storage tank and how this innovative technology will mitigate risk in the cell and gene therapy supply chain.

In cell and gene therapies, your process is the product. Our team of experts develops, defines, and refines processes for maximum efficiency and scale.

Affinity is the driving force behind everything we do. It's reflected in our deep commitment to our clients, our dedicated teams, and ultimately, the patients who depend on life-changing therapies.

With over 1,800 unique cell line models engineered by the scientists and technology developers at Applied StemCell, you can be confident in the quality and reliability of our service.

With a simple quote and 10 mg of your research grade transgene plasmid, Viralgen can perform a small scale feasibility study, including downstream purification.

Partner with a trusted manufacturing services partner for cell therapy companies. We provide expert services, including access to CMC development and clinical manufacturing for cell therapy.